Nyxoah S.A. (NYXH)

10.62 -0.14 (-1.30%) At close: 04:00PM EDT

Nyxoah S.A.

Rue Edouard Belin 12
Mont-Saint-Guibert 1435
Belgium
32 10 22 23 55
https://www.nyxoah.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full-time employees: 146

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Robert Taub MBA	Co-Founder & Chairman	136.56k	N/A	1947
Mr. Olivier Taelman	CEO & Executive Director	675.3k	N/A	1972
Mr. Loic Moreau	Chief Financial Officer	339.2k	N/A	1981
Mr. Bruno Onkelinx	Chief Technology Officer	N/A	N/A	N/A
Mikaela Kirkwood	Corporate Communication & Investor Relations Manager	N/A	N/A	N/A
Ms. An Moonen	General Counsel	N/A	N/A	N/A
Mr. Remi Renard	Vice President of Market & Market Access	N/A	N/A	N/A
Ms. Inge Vanwittenbergh	Global Human Resource Director	N/A	N/A	N/A
Mr. David M. DeMartino	Chief Strategy Officer	N/A	N/A	N/A
Mr. Jeyakumar Subbaroyan	Chief Clinical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Corporate governance

Nyxoah S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.